SCHEMBL2373586

SCHEMBL2373586

COC(=O)[C@H](CO)NCc1ccc(-c2ccccn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.44
EPHX1 P07099 1/20 0.44
EPHX2 P34913 1/20 0.44
PDCD1 Q15116 3/20 0.43
CD274 Q9NZQ7 3/20 0.43
F2 P00734 1/20 0.43
F10 P00742 1/20 0.43
PRSS1 P07477 1/20 0.43
CDK2 P24941 5/20 0.41
CDK5 Q00535 5/20 0.41
CDK9 P50750 4/20 0.41
DYRK1A Q13627 4/20 0.41
CCNT1 O60563 3/20 0.41
CCNA2 P20248 3/20 0.41
CDK5R1 Q15078 3/20 0.41
CSNK1A1 P48729 2/20 0.41
CCNA1 P78396 2/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2373591 1.00 CYP2D6 (0.44) CYP2D6EPHX1EPHX2PDCD1CD274
SCHEMBL1124616 0.88 ATM (0.51) CYP2D6EPHX1EPHX2F2F10
SCHEMBL1124614 0.88 ATM (0.51) CYP2D6EPHX1EPHX2F2F10
SCHEMBL2374008 0.85 CYP26A1 (0.43) CYP2D6EPHX1EPHX2F2F10
SCHEMBL2374019 0.85 CYP26A1 (0.43) CYP2D6EPHX1EPHX2F2F10
SCHEMBL2373970 0.82 EPHX1 (0.39) CYP2D6EPHX1EPHX2F2F10
SCHEMBL2373976 0.82 EPHX1 (0.39) CYP2D6EPHX1EPHX2F2F10
SCHEMBL2375304 0.82 EPHX1 (0.42) CYP2D6EPHX1EPHX2F2F10
SCHEMBL2375597 0.81 SIRT2 (0.42) CYP2D6EPHX1EPHX2F2F10
SCHEMBL2373607 0.81 SIRT2 (0.44) CYP2D6EPHX1EPHX2F2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 CYP2D6 1915/4885EPHX1 1866/4885EPHX2 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.